Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

96 THE PREMENSTRUAL SYNDROMES
insulin-induced hypoglycaemia. Clin Endocrinol (Oxf) 2000;
52:781–7.
91. Galliven EA, Singh A, Michelson D et al. Hormonal and metabolic
responses to exercise across time of day and menstrual
cycle phase. J Appl Physiol 1997; 83:1822–31.
92. Altemus M, Roca C, Galliven E et al. Increased vasopressin and
adrenocorticotropin responses to stress in the midluteal phase
of the menstrual cycle. J Clin Endocrinol Metab 2001;
86:2525–30.
93. Roca CA, Schmidt PJ, Altemus M et al. Differential menstrual
cycle regulation of hypothalamic–pituitary–adrenal axis in women
with premenstrual syndrome and controls. J Clin Endocrinol
Metab 2003; 88:3057–63.
94. Keller-Wood M, Silbiger J, Wood CE. Progesterone attenuates
the inhibition of adrenocorticotropin responses by cortisol in
nonpregnant ewes. Endocrinology 1988; 123:647–51.
95. Turner BB. Influence of gonadal steroids on brain corticosteriod
receptors: a minireview. Neurochem Res 1997; 22:1375–85.
96. Patchev VK, Almeida OFX. Gonadal steroids exert facilitating
and ‘buffering’ effects on glucocorticoid-mediated transcriptional
regulation of corticotropin-releasing hormone and corticosteroid
receptor genes in rat brain. J Neurosci 1996; 16:7077–84.
97. Young EA. The role of gonadal steroids in hypothalamic–
pituitary–adrenal axis regulation. Crit Rev Neurobiol 1995;
9:371–81.
98. Smith SS, Gong QH, Hsu F-C et al. GABA A receptor alpha-4
subunit suppression prevents withdrawal properties of an endogenous
steroid. Nature 1998; 392:926–30.
99. Spruce BA, Baylis PH, Burd J et al. Variation in osmoregulation
of arginine vasopressin during the human menstrual cycle. Clin
Endocrinol 1985; 22:37–42.
100. Wyatt K, Dimmock P, Jones P et al. Efficacy of progesterone and
progestogens in management of premenstrual syndrome: systematic
review. BMJ 2001; 323:776–80.
101. Freeman E, Rickels K, Sondheimer SJ et al. Ineffectiveness of
progesterone suppository treatment for premenstrual syndrome.
JAMA 1990; 264:349–53.
102. Freeman EW, Rickels K, Sondheimer SJ et al. A double-blind
trial of oral progesterone, alprazolam, and placebo in treatment
of severe premenstrual syndrome. JAMA 1995; 274:51–7.
103. Schmidt PJ, Nieman LK, Grover GN et al. Lack of effect of
induced menses on symptoms in women with premenstrual syndrome.
N Engl J Med 1991; 324:1174–9.
104. Cullberg J. Mood changes and menstrual symptoms with different
gestagen/estrogen combinations: a double blind comparison
with a placebo. Acta Psychiatr Scand 1972; 236(Suppl):1–86.
105. Kutner SJ, Brown WL. Types of oral contraceptives, depression
and premenstrual symptoms. J Nerv Ment Dis 1972; 155:153–62.
106. Graham CA, Sherwin BB. The relationship between retrospective
premenstrual symptom reporting and present oral contraceptive
use. J Psychosom Res 1987; 31:45–53.
107. Lewis A, Hoghughi M. An evaluation of depression as a side
effect of oral contraceptives. Br J Psychiatry 1969; 115:697–701.
108. Woods NF, Most A, Dery GK. Prevalence of perimenstrual
symptoms. Am J Public Health 1982; 72:1257–64.
109. Marriott A, Faragher EB. An assessment of psychological state
associated with the menstrual cycle in users of oral contraception.
J Psychosom Res 1986; 30:41–7.
110. Slade P. Premenstrual emotional changes in normal women: fact
or fiction? J Psychosom Res 1984; 28:1–7.
111. Sveindottir H, Backstrom T. Prevalence of menstrual cycle
symptom cyclicity and premenstrual dysphoric disorder in a
random sample of women using and not using oral contraceptives.
Acta Obstet Gynecol Scand 2001; 79:405–13.
112. Andersch B, Hahn L. Premenstrual complaints. II. Influence of
oral contraceptives. Acta Obstet Gynecol Scand 1981; 60:579–83.
113. Glick ID, Bennett SE. Psychiatric complications of progesterone
and oral contraceptives. J Clin Psychopharmacol 1981; 1:350–67.
114. Herzberg BN, Johnson AL, Brown S. Depressive symptoms and
oral contraceptives. Br Med J 1970; 4:142–5.
115. Kutner SJ, Phillips NR, Hoag EJ. Oral contraceptives, personality,
and changes in depression. Contraception 1971; 4:327–36.
116. Moos RH. Psychological aspects of oral contraceptives. Arch
Gen Psychiatry 1968; 19:87–94.
117. Freeman EW, Sondheimer S, Weinbaum PJ et al. Evaluating premenstrual
symptoms in medical practice. Obstet Gynecol 1985;
65:500–5.
118. Graham CA, Sherwin BB. A prospective treatment study of
premenstrual symptoms using a triphasic oral contraceptive.
J Psychosom Res 1992; 36:257–66.
119. Graham CA, Sherwin BB. The relationship between mood and
sexuality in women using an oral contraceptive as a treatment
for premenstrual symptoms. Psychoneuroendocrinology 1993;
18:273–81.
120. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique
oral contraceptive in the treatment of premenstrual dysphoric
disorder. J Womens Health Gend Based Med 2001; 10:561–9.
121. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new
low-dose oral contraceptive with drospirenone in premenstrual
dysphoric disorder. Obstet Gynecol 2005; 106:492–501.
122. Watson NR, Savvas M, Studd JWW et al. Treatment of severe
premenstrual syndrome with oestradiol patches and cyclical oral
norethisterone. Lancet 1989; 334:730–2.
123. Watson NR, Studd JWW, Savvas M et al. The long-term effects
of estradiol implant therapy for the treatment of premenstrual
syndrome. Gynecol Endocrinol 1990; 4:99–107.
124. Smith RNJ, Studd JWW, Zamblera D et al. A randomised comparison
over 8 months of 100 mg and 200 mg twice weekly
doses of transdermal oestradiol in the treatment of severe premenstrual
syndrome. Br J Obstet Gynaecol 1995; 102:475–84.
125. Davis SR. Androgen treatment in women. Med J Aust 1999;
170:545–9.
126. Buckler HM, Misra R, Cantrill JA et al. The use of low dose
(100 mg) testosterone implants in severe premenstrual syndrome
(PMS). J Endocrinol 1989; 123:34.
127. Sheffield B, Buckler HM, Cantrill JA et al. Double-blind
crossover trial of low dose testosterone implants in severe premenstrual
syndrome (PMS). J Endocrinol 1989; 121:183.
128. Dhar V, Murphy BEP. Double-blind randomized crossover trial
of luteal phase estrogens (Premarin) in the premenstrual syndrome
(PMS). Psychoneuroendocrinology 1990; 15:489–93.
129. Halbreich U, Rojansky N, Palter S. Elimination of ovulation and
menstrual cyclicity (with danazol) improves dysphoric premenstrual
syndromes. Fertil Steril 1991; 56:1066–9.
130. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebocontrolled,
crossover trial of danazol for the treatment of premenstrual
syndrome. Psychoneuroendocrinology 1995; 20:193–209.
131. Rubinow DR, Hoban MC, Grover GN et al. Changes in plasma
hormones across the menstrual cycle in patients with menstrually
related mood disorder and in control subjects. Am J Obstet
Gynecol 1988; 158:5–11.
132. Backstrom T, Sanders D, Leask R et al. Mood, sexuality, hormones,
and the menstrual cycle: II. Hormone levels and their relationship to
the premenstrual syndrome. Psychosom Med 1983; 45:503–7.
133. Wang M, Seippel L, Purdy RH et al. Relationship between
symptom severity and steroid variation in women with premenstrual
syndrome: study on serum pregnenolone, pregnenolone
sulfate, 5�-pregnane-3,20-dione and 3�-hydroxy-5�-pregnan-
20-one. J Clin Endocrinol Metab 1996; 81:1076–82.
134. Redei E, Freeman EW. Daily plasma estradiol and progesterone
levels over the menstrual cycle and their relation to premenstrual
symptoms. Psychoneuroendocrinology 1995; 20:259–67.